Facebook
Twitter
LinkedIn
ForwardHow to Manage JAK Inhibition in Patients Undergoing HCT: Applying the Latest Clinical Evidence to Improve Patient Outcomes in Myelofibrosis
Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decisions, including the timing of HCT, and newer evidence suggests that next-generation JAK inhibitors may also play a role in challenging treatment settings defined by failure of upfront JAK inhibitor therapy. Clinicians therefore should be prepared to develop truly personalized, newer therapeutic strategies for MF management that consider all available options—from targeted agents to supportive care, as well as HCT—and address the role of JAK inhibitors in patients who are transplant candidates and determine their role before and, possibly, after transplantation
In this activity based on a recent live web broadcast, a panel of experts describes the current therapeutic landscape of MF, including JAK inhibitors and HCT. They also review evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in MF.
This activity can be accessed using the following URL: www.peerview.com/MME
Target Audience
- Hematologists
- Medical Oncologists
- BMT Specialists
- BMT Nurse Specialist
- Other Clinicians Involved in the Management of Myelofibrosis
Learning Objectives
| • | Describe modern diagnostic and prognostic models, as well as molecular and clinical features that are useful for capturing myelofibrosis (MF) presentations, including primary MF and post-PV/ET MF |
| • | Review the current therapeutic role of JAK inhibitors and allogeneic hematopoietic cell transplantation (HCT), including reduced-intensity transplant, in the management of MF |
| • | Cite recent safety and efficacy evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in the management of MF |
| • | Integrate modern JAK inhibitor-based regimens into risk-adapted treatment plans for patients with symptomatic MF, including those who are eligible for allogeneic transplantation or as sequential options in the non-HCT setting |
Support Statement
This activity is supported through educational grants from AbbVie, Bristol Myers Squibb, and Incyte Corporation.
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Chair & Presenter
Ruben A. Mesa, MD, FACP
Executive Director
Mays Cancer Center at UT Health San Antonio MD Anderson
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
San Antonio, Texas
Ruben A. Mesa, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Blueprint Medicines Corporation; Celgene Corporation; Hoffmann-La Roche Ltd.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Sierra Oncology, Inc.
Grant/Research Support from Constellation Pharmaceuticals; CTI BioPharma Corp.; Incyte Corporation; Novartis Pharmaceuticals Corporation; and Promedior, Inc.
Co-Chair & Presenter
Jeanne M. Palmer, MD
Associate Professor, Division of Hematology and Oncology
Vice Chair and Section Lead, Division of Hematology
Program Director, Blood and Marrow Transplant Program
Mayo Clinic
Phoenix, Arizona
Jeanne M. Palmer, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for PharmaEssentia.
Grant/Research Support from Constellation Pharmaceuticals; CTI BioPharma Corp.; PharmaEssentia; Protagonist Therapeutics, Inc.; and Sierra Oncology, Inc.
CME Reviewer
Anita D’Souza, MD
Anita D’Souza, MD, has no financial interests/relationships or affiliations in relation to this activity.
Medical Director
Monalisa Singh, MD, PhD
PVI, PeerView Institute for Medical Education
Monalisa Singh, MD, PhD, has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.